Even when DKD is believed the sole pathology, there is still merit in being certain that this is indeed the case, because once again, the prognosis might also differ significantly from the situation where NDKD is present, e.g., SGLT-2 inhibitor therapy might be less effective if NDKD co-exists. This evidence concerns the gene SLC5A2 and diabetic kidney disease.